Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1166058

Cover Image

PUBLISHER: Transparency Market Research | PRODUCT CODE: 1166058

Chronic Obstructive Pulmonary Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

PUBLISHED:
PAGES: 241 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5795
PDF (Multi-user License)
USD 8795
PDF (Corporate License)
USD 11795

Add to Cart

TMR's report on the global chronic obstructive pulmonary disease (COPD) treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global chronic obstructive pulmonary disease (COPD) treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic obstructive pulmonary disease (COPD) treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the chronic obstructive pulmonary disease (COPD) treatment market.

The report delves into the competitive landscape of the global chronic obstructive pulmonary disease (COPD) treatment market. Key players operating in the global chronic obstructive pulmonary disease (COPD) treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global chronic obstructive pulmonary disease (COPD) treatment market profiled in this report.

Product Code: TMRGL73763

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlight

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Regulatory Scenario by Region/globally
  • 5.2. Reimbursement Scenario by Region/globally
  • 5.3. Pipeline Analysis
  • 5.4. Technological Advancements
  • 5.5. Pricing Analysis (Brand pricing, Average Selling Price by Region/Country)
  • 5.6. Disease Prevalence & Incidence Rate globally with key countries
  • 5.7. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
  • 5.8. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug Class, 2017-2031
    • 6.3.1. Combination Therapy
      • 6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 6.3.1.3. Triple therapy
      • 6.3.1.4. Others
    • 6.3.2. Bronchodilators
      • 6.3.2.1. Long Acting Beta Agonist (LABA)
      • 6.3.2.2. Short Acting Beta Agonist (SABA)
      • 6.3.2.3. Long Acting Muscarinic Antagonist (LAMA)
    • 6.3.3. Corticosteroids
    • 6.3.4. Phosphodiesterase Type 4 Inhibitor
    • 6.3.5. Mucokinetics
    • 6.3.6. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Type, 2017-2031
    • 7.3.1. Chronic Bronchitis
    • 7.3.2. Emphysema
  • 7.4. Market Attractiveness Analysis, by Type

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
  • 8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug Class, 2017-2031
    • 10.2.1. Combination Therapy
      • 10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 10.2.1.3. Triple therapy
      • 10.2.1.4. Others
    • 10.2.2. Bronchodilators
      • 10.2.2.1. Long Acting Beta Agonist (LABA)
      • 10.2.2.2. Short Acting Beta Agonist (SABA)
      • 10.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
    • 10.2.3. Corticosteroids
    • 10.2.4. Phosphodiesterase Type 4 Inhibitor
    • 10.2.5. Mucokinetics
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Type, 2017-2031
    • 10.3.1. Chronic Bronchitis
    • 10.3.2. Emphysema
  • 10.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By Type
    • 10.6.3. By Distribution Channel
    • 10.6.4. By Country

11. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Drug Class, 2017-2031
    • 11.2.1. Combination Therapy
      • 11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 11.2.1.3. Triple therapy
      • 11.2.1.4. Others
    • 11.2.2. Bronchodilators
      • 11.2.2.1. Long Acting Beta Agonist (LABA)
      • 11.2.2.2. Short Acting Beta Agonist (SABA)
      • 11.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
    • 11.2.3. Corticosteroids
    • 11.2.4. Phosphodiesterase Type 4 Inhibitor
    • 11.2.5. Mucokinetics
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Type, 2017-2031
    • 11.3.1. Chronic Bronchitis
    • 11.3.2. Emphysema
  • 11.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.4.1. Hospital Pharmacies
    • 11.4.2. Retail Pharmacies
    • 11.4.3. Online Pharmacies
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Spain
    • 11.5.5. Italy
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By Type
    • 11.6.3. By Distribution Channel
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Drug Class, 2017-2031
    • 12.2.1. Combination Therapy
      • 12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 12.2.1.3. Triple therapy
      • 12.2.1.4. Others
    • 12.2.2. Bronchodilators
      • 12.2.2.1. Long Acting Beta Agonist (LABA)
      • 12.2.2.2. Short Acting Beta Agonist (SABA)
      • 12.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
    • 12.2.3. Corticosteroids
    • 12.2.4. Phosphodiesterase Type 4 Inhibitor
    • 12.2.5. Mucokinetics
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Type, 2017-2031
    • 12.3.1. Chronic Bronchitis
    • 12.3.2. Emphysema
  • 12.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies
    • 12.4.3. Online Pharmacies
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By Type
    • 12.6.3. By Distribution Channel
    • 12.6.4. By Country/Sub-region

13. Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Drug Class, 2017-2031
    • 13.2.1. Combination Therapy
      • 13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 13.2.1.3. Triple therapy
      • 13.2.1.4. Others
    • 13.2.2. Bronchodilators
      • 13.2.2.1. Long Acting Beta Agonist (LABA)
      • 13.2.2.2. Short Acting Beta Agonist (SABA)
      • 13.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
    • 13.2.3. Corticosteroids
    • 13.2.4. Phosphodiesterase Type 4 Inhibitor
    • 13.2.5. Mucokinetics
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Type, 2017-2031
    • 13.3.1. Chronic Bronchitis
    • 13.3.2. Emphysema
  • 13.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.4.1. Hospital Pharmacies
    • 13.4.2. Retail Pharmacies
    • 13.4.3. Online Pharmacies
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By Type
    • 13.6.3. By Distribution Channel
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Drug Class, 2017-2031
    • 14.2.1. Combination Therapy
      • 14.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
      • 14.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
      • 14.2.1.3. Triple therapy
      • 14.2.1.4. Others
    • 14.2.2. Bronchodilators
      • 14.2.2.1. Long Acting Beta Agonist (LABA)
      • 14.2.2.2. Short Acting Beta Agonist (SABA)
      • 14.2.2.3. Long Acting Muscarinic Antagonist (LAMA)
    • 14.2.3. Corticosteroids
    • 14.2.4. Phosphodiesterase Type 4 Inhibitor
    • 14.2.5. Mucokinetics
    • 14.2.6. Others
  • 14.3. Market Value Forecast, by Type, 2017-2031
    • 14.3.1. Chronic Bronchitis
    • 14.3.2. Emphysema
  • 14.4. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.4.1. Hospital Pharmacies
    • 14.4.2. Retail Pharmacies
    • 14.4.3. Online Pharmacies
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Drug Class
    • 14.6.2. By Type
    • 14.6.3. By Distribution Channel
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. F. Hoffmann-La Roche Ltd.
      • 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. Financial Overview
      • 15.3.1.4. SWOT Analysis
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AstraZeneca
      • 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. Financial Overview
      • 15.3.2.4. SWOT Analysis
      • 15.3.2.5. Strategic Overview
    • 15.3.3. GlaxoSmithKline plc
      • 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. Financial Overview
      • 15.3.3.4. SWOT Analysis
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Sanofi
      • 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. Financial Overview
      • 15.3.4.4. SWOT Analysis
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Novartis AG
      • 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. Financial Overview
      • 15.3.5.4. SWOT Analysis
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Teva Pharmaceutical Industries Ltd.
      • 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. Financial Overview
      • 15.3.6.4. SWOT Analysis
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Mylan N.V.
      • 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. Financial Overview
      • 15.3.7.4. SWOT Analysis
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Boehringer Ingelheim International GmbH
      • 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. Financial Overview
      • 15.3.8.4. SWOT Analysis
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Sunovion Pharmaceuticals Inc. (Sumitomo Dainippon Pharma Co., Ltd.)
      • 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. Financial Overview
      • 15.3.9.4. SWOT Analysis
      • 15.3.9.5. Strategic Overview
    • 15.3.10. CHIESI Farmaceutici S.p.A.
      • 15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. Financial Overview
      • 15.3.10.4. SWOT Analysis
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Orion Corporation
      • 15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. Financial Overview
      • 15.3.11.4. SWOT Analysis
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Almirall
      • 15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. Financial Overview
      • 15.3.12.4. SWOT Analysis
      • 15.3.12.5. Strategic Overview
    • 15.3.13. Theravance Biopharma
      • 15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. Financial Overview
      • 15.3.13.4. SWOT Analysis
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Verona Pharmaceuticals
      • 15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. Financial Overview
      • 15.3.14.4. SWOT Analysis
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Kyowa Hakko Kirin
      • 15.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. Financial Overview
      • 15.3.15.4. SWOT Analysis
      • 15.3.15.5. Strategic Overview
Product Code: TMRGL73763

List of Tables

  • Table 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017-2031, by Combination Therapy
  • Table 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by 2017-2031, by Bronchodilators
  • Table 04: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 07: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 08: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 09: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017-2031
  • Table 10: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017-2031
  • Table 11: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 12: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 15: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017-2031
  • Table 16: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017-2031
  • Table 17: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 18: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 19: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 20: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 21: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017-2031
  • Table 22: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017-2031
  • Table 23: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 24: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 25: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 26: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 27: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017-2031
  • Table 28: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017-2031
  • Table 29: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 30: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 31: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 32: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017-2031
  • Table 33: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Combination Therapy, 2017-2031
  • Table 34: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Bronchodilators, 2017-2031
  • Table 35: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Type, 2017-2031
  • Table 36: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Drug Class, 2021
  • Figure 03: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Type, 2021
  • Figure 04: Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share, by Distribution Channel 2021
  • Figure 05: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 06: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 07: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Combination Therapy, 2017-2031
  • Figure 08: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Bronchodilators, 2017-2031
  • Figure 09: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Corticosteroids 2017-2031
  • Figure 10: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Phosphodiesterase Type 4 Inhibitor, 2017-2031
  • Figure 11: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Mucokinetics 2017-2031
  • Figure 12: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn), by Others, 2017-2031
  • Figure 13: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 14: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 15: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Chronic Bronchitis, 2017-2031
  • Figure 16: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Emphysema, 2017-2031
  • Figure 17: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 18: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 19: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Hospital Pharmacies, 2017-2031
  • Figure 20: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Retail Pharmacies, 2017-2031
  • Figure 21: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Online Pharmacies, 2017-2031
  • Figure 22: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 23: Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 24: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 25: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 26: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 27: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 28: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 29: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 30: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 31: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 32: North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 34: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 35: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 37: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 38: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 39: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 40: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 41: Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 43: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 44: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 45: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 46: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 47: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 48: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 49: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 50: Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 53: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 54: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 55: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 56: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 57: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 58: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 59: Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 63: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2021 and 2031
  • Figure 64: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 65: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Type, 2021 and 2031
  • Figure 66: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Type, 2022-2031
  • Figure 67: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2021 and 2031
  • Figure 68: Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 69: Company Share Analysis, 2021
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!